Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Top Cited Papers
- 1 January 2005
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 365 (9453) , 60-62
- https://doi.org/10.1016/s0140-6736(04)17666-6
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized TrialJNCI Journal of the National Cancer Institute, 2001
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998